【CLAIMS】

【Claim 1】

Use of a pharmaceutical composition in the manufacture of a medicament for preventing peptic ulcer, the pharmaceutical composition comprising tegoprazan which is a compound represented by the following Formula 1, an optical isomer thereof, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof, or a mixture thereof,

wherein the peptic ulcer is caused by administration of a non-steroidal anti-inflammatory drug (NSAID),

wherein the pharmaceutical composition is to be administered to a subject who takes the non-steroidal anti-inflammatory drug:

[Formula 1]



【Claim 2】

The use of claim 1, the pharmaceutical composition comprises the tegoprazan, optical isomer thereof, pharmaceutically acceptable salt thereof, hydrate or solvate thereof, or mixture thereof in an amount of 25 mg to 50 mg as tegoprazan.

【Claim 3】

The use of claim 1, the pharmaceutical composition comprises the tegoprazan, optical isomer thereof, pharmaceutically acceptable salt thereof, hydrate or solvate thereof, or mixture thereof in an amount of 25 mg as tegoprazan.

【Claim 4】

The use of claim 2, the pharmaceutical composition is to be administered to a subject who experienced peptic ulcer before administration of the pharmaceutical composition.

【Claim 5】

The use of claim 4, wherein the subject is a person whose peptic ulcer has been treated before administration of the pharmaceutical composition.

【Claim 6】

The use of claim 2, the pharmaceutical composition is for preventing recurrence of the peptic ulcer.

【Claim 7】

The use of claim 1, the pharmaceutical composition further comprises a non-steroidal anti-inflammatory drug.

【Claim 8】

The use of claim 1, the pharmaceutical composition is to be co-administered with a non-steroidal anti-inflammatory drug.

【Claim 9】

The use of claim 7 or 8, wherein the non-steroidal anti-inflammatory drug is one or more selected from the group consisting of non-selective NSAIDs and COX-2 selective inhibitors.

【Claim 10】

The use of claim 7 or 8, wherein the non-steroidal anti-inflammatory drug is one or more selected from the group consisting of salicylates, propionic acid derivatives, acetic acid derivatives, enolic acid (oxicam) derivatives, anthranilic acid derivative (fenamates), selective Cox-2 inhibitors (coxibs), sulfonanilides and clonixin.

【Claim 11】

The use of claim 7 or 8, wherein the non-steroidal anti-inflammatory drug is one or more selected from the group consisting of propionic acid derivatives, acetic acid derivatives and selective Cox-2 inhibitor (coxibs).

【Claim 12】

The use of claim 11, wherein the non-steroidal anti-inflammatory drug is one or more selected from the group consisting of naproxen, aceclofenac and celecoxib.

【Claim 13】

The use of claim 2, the pharmaceutical composition is to

be administered once a day.

【Claim 14】

The use of claim 2, the pharmaceutical composition is formulated in a unit dosage form.

【Claim 15】

The use of claim 7 or 8, wherein the pharmaceutical composition and the non-steroidal anti-inflammatory drug are each independently formulated in separate unit dosage forms or in a single unit dosage form.